Precision BioSciences to Participate in Upcoming Guggenheim Healthcare Talks Conference

Rhea-AI Summary

Precision BioSciences, Inc. (NASDAQ: DTIL), a clinical stage gene editing company, announced its participation in the Guggenheim Healthcare Talks – Genomic Medicines and Rare Disease Days on April 3-4, 2023. The company’s presentation is scheduled for April 3, 2023, at 3:20 PM ET, at the Lotte New York Palace Hotel. It will be accessible via a recorded webcast on Precision’s website under the Investors section. The company focuses on ex vivo and in vivo gene editing therapies utilizing its proprietary ARCUS® platform, aimed at treating genetic and infectious diseases without adequate existing treatments.

DURHAM, N.C.--(BUSINESS WIRE)-- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the Guggenheim Healthcare Talks – Genomic Medicines and Rare Disease Days taking place April 3-4, 2023.

Details for the company presentation are as follows:
Date: Monday, April 3, 2023
Time: 3:20 PM ET
Location: Lotte New York Palace Hotel

The presentation will be available via a recorded webcast accessible on Precision’s website in the Investors section under Events & Presentations: https://investor.precisionbiosciences.com/events-and-presentations. An archived replay will be available for approximately 30 days following the event.

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple ex vivo “off-the-shelf” CAR T immunotherapy clinical candidates and several in vivo gene editing candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230327005144/en/

Investor and Media Contact:

Mei Burris

Director, Investor Relations & Finance

Mei.burris@precisionbiosciences.com

Source: Precision BioSciences, Inc.

FAQ

When is Precision BioSciences' presentation at the Guggenheim Healthcare Talks?

Precision BioSciences' presentation is scheduled for April 3, 2023, at 3:20 PM ET.

Where will the Guggenheim Healthcare Talks take place?

The Guggenheim Healthcare Talks will be held at the Lotte New York Palace Hotel.

How can I access the presentation by Precision BioSciences?

The presentation will be available via a recorded webcast on Precision's website in the Investors section.

What is the focus of Precision BioSciences' research?

Precision BioSciences focuses on developing gene editing therapies, including CAR T immunotherapy candidates and treatments for genetic diseases.

What is the significance of the ARCUS® platform developed by Precision BioSciences?

The ARCUS® platform is designed for precise genome editing, aimed at improving therapeutic safety and efficacy.